Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00368836 · ClinicalTrials.gov registry record · Phase 2
Breath Analysis Technique to Diagnose Pulmonary Embolism
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 475
- Enrollment target
NCT00368836 is a Phase 2 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 475 participants.
The verdict
NCT00368836, a Phase 2 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 475 participants
- Enrollment target
Study Summary
A pulmonary embolism (PE) is a blockage in one of the arteries of the lungs, and is usually caused by a traveling blood clot. The D-dimer blood test is currently used to diagnose PEs, but it is not always accurate for individuals who have recently undergone surgery or who have inflammatory-provoking diseases. The purpose of this study is to evaluate the effectiveness of the Carboximeter, a new PE diagnostic device that measures carbon dioxide (CO2) and oxygen (O2) output, in individuals at risk for developing PEs.
Interventions
- DEVICE BreathScreen PE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 475 participants |
| Start Date | 2006-01 |
| Est. Completion | 2008-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00368836
The ClinicalTrials.gov registry entry for NCT00368836 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 475 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BreathScreen PE is the first listed.
NCT00368836 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00368836 about?
NCT00368836 is a clinical study titled "Breath Analysis Technique to Diagnose Pulmonary Embolism". A pulmonary embolism (PE) is a blockage in one of the arteries of the lungs, and is usually caused by a traveling blood clot. The D-dimer blood test is currently used to diagnose PEs, but it is not always accurate for individuals who have recently undergone surgery or who have inflammatory-provoking...
What is the current status of trial NCT00368836?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 475 participants. The study started on 2006-01. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00368836?
The interventions under investigation include: BreathScreen PE (DEVICE).
Who is sponsoring clinical trial NCT00368836?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.